Phenotype | Brief logical description | Prior development |
3-point MACE | Condition record of acute myocardial infarction, haemorrhagic or ischaemic stroke or sudden cardiac death during an inpatient or ER visit | 49–61 |
4-point MACE | 3-point MACE+inpatient or ER visit (hospitalisation) with heart failure condition record | 44 49–67 |
Acute myocardial infarction | Condition record of acute myocardial infarction during an inpatient or ER vist | 49–54 |
Acute renal failure | Condition record of acute renal failure during an inpatient or ER visit | 47 68–75 |
Glycaemic control | First haemoglobin A1c measurement with value ≤7% | 76 |
Hospitalisation with heart failure | Inpatient or ER visit with heart failure condition record | 44 62–67 |
Measured renal dysfunction | First creatinine measurement with value >3 mg/dL | 75 |
Coronary revascularisation | Procedure record of percutaneous coronary intervention or coronary artery bypass grafting during an inpatient or ER visit | 45 |
Stroke | Condition record of haemorrhagic or ischaemic stroke during an inpatient or ER visit | 55–60 |
Sudden cardiac death | Condition record of sudden cardiac death during an inpatient or ER visit | 52 61 |
Abnormal weight gain | Abnormal weight gain record of any type; successive records with >90-day gap are considered independent episodes; note, weight measurements not used | 77 |
Abnormal weight loss | Abnormal weight loss record of any type; successive records with >90-day gap are considered independent episodes; note, weight measurements not used | 78 |
Acute pancreatitis | Condition record of acute pancreatitis during an inpatient or ER visit | 79–82 |
All-cause mortality | Death record of any type | 52 83 84 |
Bladder cancer | Malignant tumour of urinary bladder condition record of any type; limited to earliest event per person | |
Bone fracture | Bone fracture condition record of any type; successive records with >90-day gap are considered independent episodes | |
Breast cancer | Malignant tumour of breast condition record of any type; limited to earliest event per person | |
Diabetic ketoacidosis | Diabetic ketoacidosis condition record during an inpatient or ER visit | 46 85 |
Diarrhoea | Diarrhoea condition record of any type; successive records with >30-day gap are considered independent episodes | 86–88 |
GU infection | Condition record of any type of genital or urinary tract infection during an outpatient or ER vists | 89 |
Hyperkalaemia | Condition record for hyperkalaemia or potassium measurements >5.6 mmol/L; successive records with >90-day gap are considered independent episodes | 90–92 |
Hypoglycaemia | Hypoglycaemia condition record of any type; successive records with >90-day gap are considered independent episodes | 93 |
Hypotension | Hypotension condition record of any type; successive records with >90-day gap are considered independent episodes | 94 |
Joint pain | Joint pain condition record of any type; successive records with >90-day gap are considered independent episodes | |
Lower extremity amputation | Procedure record of below knee lower extremity amputation during inpatient or outpatient visit | 44 48 |
Nausea | Nausea condition record of any type; successive records with >30-day gap are considered independent episodes | 95–97 |
Peripheral oedema | Oedema condition record of any type; successive records with >180-day gap are considered independent episodes | |
Photosensitivity | Condition record of drug-induced photosensitivity during any type of visit | |
Renal cancer | Primary malignant neoplasm of kidney condition record of any type; limited to earliest event per person | |
Thyroid tumour | Neoplasm of thyroid gland condition record of any type; limited to earliest event per person | |
Venous thromboembolism | Venous thromboembolism condition record of any type; successive records with >180-day gap are considered independent episodes | 98–101 |
Vomiting | Vomiting condition record of any type; successive records with >30-day gap are considered independent episodes | 95–97 |
ER, emergence room; GU, genitourinary; LEGEND-T2DM, large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus; MACE, major adverse cardiovascular events.